Evidence map›Paper›PMID 41862477›Full record

ArticleNPJ Parkinson's disease2026

Profiling of 5-hydroxymethylcytosine in blood reveals preferential enrichment at exon-intron junctions and predictive value for Parkinson's disease.

Philipp Antczak, Peter Brandt, Lav Radosavljević, Per Svenningsson, Joëlle Rüegg, Kristina Bečanović

Abstract read
In one paragraph

Article in NPJ Parkinson's disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Philipp AntczakDepartment II of Internal Medicine, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany.
Peter Brandt *Department of Medicinal Chemistry, Uppsala University, Uppsala, Sweden.
Lav Radosavljević *Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom.
Per SvenningssonDepartment of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
Joëlle RüeggDepartment of Organismal Biology, Uppsala University, Uppsala, Sweden.
Kristina BečanovićDepartment of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden. kristina.becanovic@ki.se.

Funding

CECAD 390661388
6 · The paper itself

Abstract

5-methylcytosine (5mC) and 5-hydroxymethylcytosine (5hmC) are epigenetic modifications increasingly recognized for their roles in Parkinson's disease (PD). In this study, we profiled 5mC and 5hmC in blood samples from individuals with PD to explore their relevance to disease status and progression. We observed significantly reduced global 5hmC levels in peripheral blood mononuclear cells (PBMCs) from PD cases compared to controls. Using the Illumina EPIC BeadArray, we conducted genome-wide analyses of 5mC and 5hmC in a subset of PD cases and controls to explore methylation and hydroxymethylation patterns. We identified differentially methylated and hydroxymethylated positions and regions enriched within introns, with both types of regions showing a marked concentration near exon-intron junctions. Positional analysis relative to exon-intron junctions revealed that proximal and distal regions mapped to partially different functional themes, suggesting that genomic context provides additional biological insight. Functional enrichment analyses also highlighted distinct biological roles for 5mC and 5hmC, with associated genes implicated in neurodevelopment, vascular remodeling, and neuroimmune signaling. Additionally, we demonstrate that global 5hmC levels, in combination with age and sex, are predictive of disease status, highlighting the potential of 5hmC as a blood-based biomarker for PD.

Identifiers

PMID41862477
PMCPMC13022309

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.